These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25340007)

  • 1. Identification of immunogenic LY6K long peptide encompassing both CD4
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Imamura Y; Yatsuda J; Sayem MA; Irie A; Hamada A; Jono H; Yoshida K; Tsunoda T; Daigo Y; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Oncoimmunology; 2014; 3():e28100. PubMed ID: 25340007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Yoshimura S; Osawa R; Kuroda Y; Hirayama M; Irie A; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Int J Cancer; 2014 Jan; 134(2):352-66. PubMed ID: 24734272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.
    Hirayama M; Tomita Y; Yuno A; Tsukamoto H; Senju S; Imamura Y; Sayem MA; Irie A; Yoshitake Y; Fukuma D; Shinohara M; Hamada A; Jono H; Yuba E; Kono K; Yoshida K; Tsunoda T; Nakayama H; Nishimura Y
    Oncoimmunology; 2016 Jun; 5(6):e1123368. PubMed ID: 27471607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4
    Tsuruta M; Ueda S; Yew PY; Fukuda I; Yoshimura S; Kishi H; Hamana H; Hirayama M; Yatsuda J; Irie A; Senju S; Yuba E; Kamba T; Eto M; Nakayama H; Nishimura Y
    Oncoimmunology; 2018; 7(4):e1415687. PubMed ID: 29632734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
    Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
    Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of glypican-3-derived long peptides activating both CD8
    Sayem MA; Tomita Y; Yuno A; Hirayama M; Irie A; Tsukamoto H; Senju S; Yuba E; Yoshikawa T; Kono K; Nakatsura T; Nishimura Y
    Oncoimmunology; 2016; 5(1):e1062209. PubMed ID: 26942076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4
    Tomita Y; Nishimura Y
    Oncoimmunology; 2013 Sep; 2(9):e25801. PubMed ID: 24327937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
    Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
    J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
    Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
    Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
    Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
    Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
    Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
    Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
    Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
    Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
    Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
    Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
    Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
    Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
    zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
    J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.